Format

Send to

Choose Destination
Eur Neuropsychopharmacol. 2014 Dec;24(12):1954-60. doi: 10.1016/j.euroneuro.2014.06.008. Epub 2014 Jun 28.

Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.

Author information

1
Departments of Medicine, Pathology, Neurology, and Neurosurgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, 55 Claverick Street, Room 419, Providence, RI 02903, USA. Electronic address: Suzanne_DeLaMonte_MD@Brown.edu.

Abstract

Alzheimer׳s disease (AD) is the most common cause of dementia in North America. Growing evidence supports the concept that AD is a metabolic disease mediated by impairments in brain insulin responsiveness, glucose utilization, and energy metabolism, which lead to increased oxidative stress, inflammation, and worsening of insulin resistance. In addition, metabolic derangements directly contribute to the structural, functional, molecular, and biochemical abnormalities that characterize AD, including neuronal loss, synaptic disconnection, tau hyperphosphorylation, and amyloid-beta accumulation. Because the fundamental abnormalities in AD represent effects of brain insulin resistance and deficiency, and the molecular and biochemical consequences overlap with Type 1 and Type 2 diabetes, we suggest the term "Type 3 diabetes" to account for the underlying abnormalities associated with AD-type neurodegeneration. In light of the rapid increases in sporadic AD prevalence rates and vastly expanded use of nitrites and nitrates in foods and agricultural products over the past 30-40 years, the potential role of nitrosamine exposures as mediators of Type 3 diabetes is discussed.

KEYWORDS:

Alzheimer׳s; Diabetes; Glucose Metabolism; Insulin resistance; Nitrosamines

PMID:
25088942
PMCID:
PMC4444430
DOI:
10.1016/j.euroneuro.2014.06.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center